Devereux G, Fishwick K, Aiken T C, Bourke S J, Hendrick D J
Department of Respiratory Medicine, Royal Victoria Infirmary, University of Newcastle upon Tyne.
Br J Clin Pharmacol. 1998 Jul;46(1):79-82. doi: 10.1046/j.1365-2125.1998.00039.x.
To investigate the effect of (+)-sotalol, which is not thought to possess clinically significant beta-adrenoceptor blocking activity, on airway responsiveness in subjects with mild asthma.
A placebo controlled, double-blind, single dose, cross over study, evaluating the effects of oral (+)-sotalol 300 mg and oral (+/-)-sotalol 240 mg, on airway responsiveness, FEV1, and heart rate in 18 asthmatic volunteers with quantifiable levels of airway responsiveness.
Compared with placebo, (+)-sotalol induced a significant increase in airway responsiveness, and a significant decrease in FEV1, but there was no significant change in heart rate. Following (+/-)-sotalol there was no significant effect on airway responsiveness, but there were significant decreases in FEV1 and heart rate. In one subject both (+)-sotalol and (+/-)-sotalol provoked a 49% decrement in FEV1, and in another there were decrements of 20% and 18%, respectively.
Despite theoretical considerations, it cannot be assumed that (+)-sotalol is safe in patients with asthma.
研究（+）-索他洛尔（一种被认为不具有临床显著β-肾上腺素能受体阻断活性的药物）对轻度哮喘患者气道反应性的影响。
一项安慰剂对照、双盲、单剂量、交叉研究，评估口服300毫克（+）-索他洛尔和口服240毫克（±）-索他洛尔对18名具有可量化气道反应性水平的哮喘志愿者的气道反应性、第一秒用力呼气容积（FEV1）和心率的影响。
与安慰剂相比，（+）-索他洛尔可导致气道反应性显著增加，FEV1显著降低，但心率无显著变化。服用（±）-索他洛尔后，对气道反应性无显著影响，但FEV1和心率显著降低。在一名受试者中，（+）-索他洛尔和（±）-索他洛尔均使FEV1下降49%，在另一名受试者中，分别下降20%和18%。
尽管从理论上考虑，但不能认为（+）-索他洛尔对哮喘患者是安全的。
